Janus kinase 2 (JAK2) encodes for a protein tyrosine kinase involved in cytokine receptor signaling. Mutations
in JAK2 have been identified in ALL and other hematologic malignancies.
Preclinical models have been used to test efficacy of mTOR and JAK inhibitors in
CRLF2-rearranged and JAK2-mutated high-risk precursor B-cell ALL (Maude
et al. 2011).
Suggested Citation: Brown, V., S. Borinstein, D. Friedman. 2018. JAK2. My
Cancer Genome https://www.padiracinnovation.org/content/disease/acute-lymphoblastic-leukemia/jak2/?tab=0
(Updated April 3).
Last Updated: April 3, 2018
JAK2 in Acute Lymphoblastic Leukemia
Suggested Citation: Brown, V., S. Borinstein, D. Friedman. 2014. JAK2 in Acute
Lymphoblastic Leukemia. My Cancer Genome https://www.padiracinnovation.org/content/disease/acute-lymphoblastic-leukemia/jak2/
(Updated August 8).
Last Updated: August 8, 2014
My Cancer Genome has released its new and improved cancer clinical trials search tool on our
beta website. Please visit beta.padiracinnovation.org
to check it out!